Karyopharm Therapeutics Inc KPTI
$1.96 $0.14 (7.69%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
KPTI Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Karyopharm Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Karyopharm Therapeutics Inc. Stock Analysis KPTI
United States Health Care Nano Cap Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. The company is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc (KPTI) Chart
Financial Metrics & Statements of Karyopharm Therapeutics Inc (KPTI)
FAQ's for Karyopharm Therapeutics Inc (KPTI)
- As of August 2026, Karyopharm Therapeutics Inc KPTI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Karyopharm Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Karyopharm Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Karyopharm Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Karyopharm Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Karyopharm Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Karyopharm Therapeutics Inc (KPTI)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
